Your browser doesn't support javascript.
loading
Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: An exploratory study.
Wang, H; Mendez, L C; Morton, G; Loblaw, A; Mesci, A; Chung, H T; Chan, S; Huang, X; Downes, M R; Vesprini, D; Liu, S K.
Affiliation
  • Wang H; Department of Medical Biophysics, University of Toronto, Canada; Sunnybrook Research Institute, Toronto, Canada.
  • Mendez LC; Division of Radiation Oncology, London Regional Cancer Program, London, Canada.
  • Morton G; Sunnybrook Research Institute, Toronto, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Loblaw A; Sunnybrook Research Institute, Toronto, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada; Institute of Health Policy, Management and Evaluation, Toronto, Canada.
  • Mesci A; Sunnybrook Research Institute, Toronto, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Chung HT; Sunnybrook Research Institute, Toronto, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Chan S; Sunnybrook Research Institute, Toronto, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Huang X; Sunnybrook Research Institute, Toronto, Canada.
  • Downes MR; Division of Anatomic Pathology, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Vesprini D; Sunnybrook Research Institute, Toronto, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.
  • Liu SK; Department of Medical Biophysics, University of Toronto, Canada; Sunnybrook Research Institute, Toronto, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada. Electronic address: stanley.liu@sunnybrook.ca.
Radiother Oncol ; 155: 80-85, 2021 02.
Article in En | MEDLINE | ID: mdl-33172830
ABSTRACT
This exploratory study evaluates immunological changes in high-risk Gleason 9 prostate cancer patients treated with EBRT+BT compared to EBRT alone. Notably, BT demonstrates the potential to elicit a T cell response which may support further investigation using circulating immune cells as predictive and prognostic biomarkers for radiotherapy response.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Brachytherapy Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: Radiother Oncol Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Brachytherapy Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: Radiother Oncol Year: 2021 Document type: Article